Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Momentum 2.6/10 is below the 5.0 floor at $631.00 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Counterparty: Sanofi; Concentration risk — Counterparty: Bayer.
Regeneron is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases, with $14.3B in 2025 revenues and $4.5B net income. Its two largest revenue drivers are Dupixent (dupilumab; $17.8B global sales... Read more
Sell if holding. Momentum 2.6/10 is below the 5.0 floor at $631.00 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Counterparty: Sanofi; Concentration risk — Counterparty: Bayer. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.6/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent Developments — Regeneron Pharmaceuticals, Inc.
Latest news
- Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock. - Barron's — Barron's negative
- Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug - Investor's Business Daily — Investor's Business Daily negative
- Regeneron Slumps On Unexpected Eylea Setback - Investor's Business Daily — Investor's Business Daily negative
- Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement - TradingKey — TradingKey negative
- Earnings call transcript: Regeneron Q1 2026 beats estimates, stock dips - Investing.com — Investing.com positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartySanofi10-K Item 1: 'the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated'
- HIGHcounterpartyBayer10-K Item 1: 'the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.6/10 is below the 5.0 floor at $631.00 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Counterparty: Sanofi; Concentration risk — Counterparty: Bayer. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $591.40. Score 5.6/10, moderate confidence.
Take-profit target: $749.98 (+19.2% upside). Prior stop was $591.40. Stop-loss: $591.40.
Concentration risk — Counterparty: Sanofi; Concentration risk — Counterparty: Bayer; Leverage penalty (D/E 8.6): -1.5.
Regeneron Pharmaceuticals, Inc. trades at a P/E of 15.4 (forward 11.7). TrendMatrix value score: 6.9/10. Verdict: Sell.
38 analysts cover REGN with a consensus score of 4.1/5. Average price target: $833.
What does Regeneron Pharmaceuticals, Inc. do?Regeneron is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes...
Regeneron is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases, with $14.3B in 2025 revenues and $4.5B net income. Its two largest revenue drivers are Dupixent (dupilumab; $17.8B global sales recorded by Sanofi, Regeneron receives profit share) and EYLEA/EYLEA HD (aflibercept; $7.9B combined, U.S. recorded by Regeneron, ex-U.S. by Bayer). Regeneron operates a large human genetics database and collaborates with Sanofi and Bayer on its two flagship product franchises.